The efficacy and tolerability of almotriptan 12.5 mg in acute migraine in patients who were poor responders to sumatriptan 50 mg: a randomized, placebo-controlled trial

被引：0

作者：

Diener, HC ^{[1
]}

机构：

[1] Univ Essen Gesamthsch, Dept Neurol, Essen, Germany

来源：

CEPHALALGIA | 2004年 / 24卷 / 09期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：795 / 796

页数：2

共 50 条

[1] Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients with previous poor response to sumatriptan 50 mg
Diener, HC
CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (10) : 1603 - 1610
[2] A double-blind, randomized, parallel-group trial of almotriptan 12.5 mg vs placebo in migraine patients who respond poorly to sumatriptan 50 mg
Diener, HC
Gebert, I
NEUROLOGY, 2004, 62 (07) : A151 - A152
[3] A double-blind, randomized, parallel-group trial of almotriptan 12.5 mg vs. placebo in migraine patients who respond poorly to sumatriptan 50 mg
Diener, HC
CEPHALALGIA, 2005, 25 (08) : 665 - 665
[4] A randomized, double-blind, placebo-controlled study of oral almotriptan 6.25 mg, 12.5 mg, and 25 mg in the acute treatment of migraine in adolescents
Linder, S. L.
Mathew, N. T.
Cady, R. K.
Finlayson, G.
Ishkanian, G.
Lewis, D. W.
Cabarrocas, X.
ANNALS OF NEUROLOGY, 2006, 60 : S152 - S152
[5] A double-blind placebo-controlled study assessing the efficacy and tolerability of 50 mg sumatriptan tablets in the acute treatment of migraine
Savani, N
Brautaset, NJ
Reunanen, M
Szirmai, I
Ashford, EA
Hassani, H
Saiers, J
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 1999, : 7 - 15
[6] Almotriptan 12.5 mg in menstrually related migraine: A randomized, double-blind, placebo-controlled study
Allais, Gianni
Bussone, Gennaro
D'Andrea, Giovanni
Moschiano, Franca
d'Onofrio, Florindo
Valguarnera, Fabio
Manzoni, Gian Camillo
Grazzi, Licia
Allais, Rita
Benedetto, Chiara
Acuto, Giancarlo
CEPHALALGIA, 2011, 31 (02) : 144 - 151
[7] A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults
Wendt, Jeanette
Cady, Roger
Singer, Richard
Peters, Kenneth
Webster, Christopher
Kori, Shashidhar
Byrd, Susan
CLINICAL THERAPEUTICS, 2006, 28 (04) : 517 - 526
[8] A randomized, prospective, cross-over, double blind, placebo-controlled multicentre study to assess the efficacy and tolerability of almotriptan 12.5 mg in menstrually-related migraine
Allais, G.
D'Andrea, G.
Moschiano, F.
d'Onofrio, F.
Valguarnera, F.
Manzoni, G.
Grazzi, L.
Benedetto, C.
Acuto, G.
Bussone, G.
CEPHALALGIA, 2009, 29 : 13 - 13
[9] Placebo-controlled trial with tolfenamic acid 200 mg and sumatriptan 100 mg in acute treatment of migraine.
Rasmussen, MJK
Hansen, AW
Schmidt-Hansen, PT
Hansen, PE
Lademann, A
Hinge, HH
CEPHALALGIA, 1999, 19 (04) : 318 - 319
[10] Treatment of osteoarthritis patients with rofecoxib 12.5 mg and celecoxib 200 mg: A randomized, placebo-controlled trial
Ruoff, G
Gilderman, L
Cohen, S
Valenzuela, C
Rodgers, A
Petruschke, R
Terschakovec, A
OSTEOARTHRITIS AND CARTILAGE, 2004, 12 : S87 - S88

← 1 2 3 4 5 →